Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MFIC Corporation to Host Second Quarter 2007 Results Conference Call/Audio Webcast
Monday August 13, 7:51 pm ET
NEWTON, Mass.--(BUSINESS WIRE)--MFIC Corporation (OTCBB: MFIC - News) announced today that it expects to release second quarter results on Tuesday, August 14, 2007. A conference call will also be held on Tuesday, August 14 at 4:00 PM Eastern Time to review the results and provide an update on the Company's progress.
Participants are invited to attend the call by visiting www.mficcorp.com or by dialing:
866-543-6411 (International: 617-213-8900)
Passcode: 43089243
A re-broadcast of the conference call will be available until August 28, 2007 and accessible by dialing:
888-286-8010 (International: 617-801-6888)
Passcode: 10716893
About MFIC Corporation:
MFIC Corporation, through its Microfluidics Division, designs, manufactures and distributes patented and proprietary high performance Microfluidizer® materials processing and formulation equipment to the biotechnology, pharmaceutical, chemical, cosmetics/personal care, and food industries. MFIC applies its 20 years of high pressure processing experience to produce the most uniform and smallest liquid and suspended solid particles available, and has provided manufacturing systems for nanoparticle products for more than 15 years.
The Company is a leader in advanced materials processing equipment for laboratory, pilot scale and manufacturing applications, offering innovative technology and comprehensive solutions for nanoparticles and other materials processing and production. More than 3,000 systems are in use and afford significant competitive and economic advantages to MFIC equipment customers.
Contact:
MFIC Corporation
Jack M. Swig, 617-969-5452
info@mfics.com
or
MacDougall Biomedical Communications
Sarah Cavanaugh, 508-647-0209
scavanaugh@macbiocom.com
Source: MFIC Corporation
Form 8-K for MFIC CORP
13-Aug-2007
Item 8.01 Other Events
As reported on a Form 4 filed with the Securities and Exchange Commission on July 26, 2007, Irwin Gruverman, a member of the Board of Directors of MFIC Corporation (the "Company"), sold 100,000 shares of the Company's common stock. In connection with several questions that the Company has been asked by Company investors concerning this sale, the Company has been informed that Mr. Gruverman sold those shares in a private, non-market transaction to an existing shareholder.
Nanotech's influence on the food industry:
http://www.azonano.com/news.asp?newsID=4672
MFIC EPS estimate message received from my online broker today:
"Q4 2007 earnings are expected to be announced on August 13, 2007 Estimates: 0.04 | 0.04 | 0.04 (High | Mean | Low)"
Note: It should have read Q2 2007.
the CEO has announced his retirement. He has over a million shares.
looks like an insider sold a few...
Microfluidics Introduces Basic “No Frills” Microfluidizer Processors for Biopharm Industry
Ideal for Pilot Production of Clinical Batches Requiring cGMP - Enhancements Available When Needed
NEWTON, Mass., July 16, 2007 – Microfluidics has introduced a basic M-700 series of Microfluidizer® high-shear fluid processors ideally suited for producing clinical batches and for scaling up to biopharmaceutical pilot production.
The well established M-7125 and M-7250 machines can now be purchased as economical basic standard biopharmaceutical packages, which include a skid mounted pharma-grade feed pump, a sanitary flush diaphragm pressure transducer with digital readout, and written certifications that all product contact surfaces within the machine and feed pump have been passivated, electro-polished and ground to a 20Ra surface finish.
In keeping with cGMP guidelines, each machine comes standard with IQ/OQ documentation, a document turnover package, on-site start-up and training and CE compliance.
As products evolve, myriad options are available that afford flexibility to the Basic package user. Options can be ordered if or when needed. These include pharma-grade heat exchangers, PLC control, temperature sensing with digital readouts, Ultra Clean In Place (UCIP), and motor starter panels.
Coupled with its patented fixed geometry interaction chambers, the M-700 series Microfluidizer processors generate a controlled rate of shear which allows bacterial, plant and mammalian cells to be safely and efficiently disrupted while enabling the highest shear rates of any fluid processor on the market today to achieve the desired product quality for nano-emulsions and nano-dispersions in the least number of passes.
About Microfluidics
Microfluidics, a wholly owned subsidiary of MFIC Corporation, is a supplier of advanced fluid processing equipment and reaction technology for laboratory, pilot scale and manufacturing applications. Microfluidics is a leader in innovative technology and comprehensive solutions for formulations requiring repeatability and for the production of uniformly distributed nanoparticles.
Microfluidics has been a worldwide supplier of Microfluidizer® high shear fluid processing systems to the Biotechnology and Pharmaceutical industries since 1984. As leader in the field, Microfluidics has enabled numerous companies and institutions to formulate, validate and produce licensed drugs for the worldwide healthcare market.
Companies seeking to produce difficult-to-formulate products or to find better methods of bio-processing can take advantage of complimentary sample testing at one of three Microfluidics facilities. Visit www.microfluidicscorp.com, email mixinginfo@mfics.com or contact Microfluidics at 800.370.5452 for application information.
CONTACT:
Lauren Purpura
Gray & Rice Public Relations
617-367-0100 ext. 123
lpurpura@gr2000.com
Downloads
20070716-1912-0C275321.jpg
Microfluidics To Showcase M-700 Microfluidizer Processor At Chem Show 2007
Source: chemicalonline.com
July 13, 2007
Newton, MA - Microfluidics will showcase the latest version of its laboratory model M-700 Microfluidizer high-shear fluid processor at the Chem Show 2007 Process Equipment & Technology Exhibition, from October 30- November 1 in New York, N.Y. The M-700 series offers pilot and production performance levels with specific features ideally suited for the industrial chemical processing of materials including coatings, waxes, inks, pigments, and sealants.
Allowing for potentially full integration and connectivity to customer SCADA or DCS systems using Microfluidics controls, the M-700 processors are capable of generating up to 40,000 psi for premium results at an affordable cost. Microfluidics guarantees scale-up from laboratory or pilot scale machines to full production machines.
The system is easy to operate and is designed for Ultra Clean In Place (UCIP). The series is also available with Ethernet communication, which connects with the customers factory automation systems.
SOURCE: Microfluidics
MFIC to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Tuesday July 10, 7:00 pm ET
NEWTON, Mass.--(BUSINESS WIRE)--(OTCBB: MFIC - News): MFIC Corporation (MFIC or the Company) announced that the Company will present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference at the Mandarin Oriental Hotel in New York City on July 11, 2007 at 4:30 p.m. Eastern Time. Jack Swig, Vice President of Corporate Development and General Counsel, will provide an overview of the Company, review key research and development accomplishments and discuss upcoming corporate initiatives. A link to a live webcast of the presentation will be available on the home page of the Company's website, www.mficcorp.com. A replay of the presentation will be available for 90 days after the conference.
About MFIC Corporation:
MFIC Corporation, through its Microfluidics Division, designs, manufactures and distributes patented and proprietary high performance Microfluidizer® materials processing and formulation equipment to the biotechnology, pharmaceutical, chemical, cosmetics/personal care, and food industries. MFIC applies its 20 years of high pressure processing experience to produce the most uniform and smallest liquid and suspended solid particles available, and has provided manufacturing systems for nanoparticle products for more than 15 years.
The Company is a leader in advanced materials processing equipment for laboratory, pilot scale and manufacturing applications, offering innovative technology and comprehensive solutions for nanoparticles and other materials processing and production. More than 3,000 systems are in use and afford significant competitive and economic advantages to MFIC equipment customers.
Contact:
MFIC Corporation
Jack M. Swig, 617-969-5452
info@mfics.com
or
MacDougall Biomedical Communications
Sarah Cavanaugh, 508-647-0209
scavanaugh@macbiocom.com
--------------------------------------------------------------------------------
Source: MFIC Corporation
Microfluidics Unveils New Technology Center
PharmacueticalOnline.com
June 29, 2007
Microfluidics, a wholly owned subsidiary of MFIC Corporation, has announced the opening of the Microfluidics Technology Center, a state-of-the-art research and discovery facility. Located at the Microfluidics company headquarters in Newton, Mass., the Center was officially unveiled during the company’s annual shareholders meeting on June 21. Microfluidics President and COO, Bob Bruno, delivered an overview of the company’s rich heritage and provided guests with a scope of what the Center will bring to existing and potential customers in the biotech, pharmaceutical, chemical, personal care and food industries.
“The opening of the Center demonstrates our ongoing commitment to advancing the fluid processing industry and to providing the highest quality of service to our customers,” said Bruno. “While we have always worked closely with customers to solve their most challenging formulation problems, the Microfluidics Technology Center will maximize this experience by providing access to leading R&D engineers and the most advanced equipment in a single-laboratory setting designed specifically with our customers’ unique needs in mind.”
Microfluidics is an industry leader in materials processing and formulation equipment, and possesses the unique ability to produce the most uniform and smallest liquid and suspended structures available for the biotech, pharmaceutical, chemical, personal care and food industries. The Microfluidics Technology Center will provide customers full access to the company’s R&D engineers and complete product suite to prepare, characterize and optimize formulation samples. Engineers will also assist customers in improving existing products through reformulation using proprietary, leading-edge, high-shear Microfluidizer® processors.
“The Microfluidics Technology Center will house our highly-specialized research team, dedicated to advancing the formulation field by developing new applications for Microfluidics’ technology and pursuing groundbreaking work in the field of nanotechnology,” said Dr. Thomai Panagiotou, vice president of research and development.
“We are very excited about the Center and believe it will serve as an innovation hub, playing a critical role in unlocking countless formulation solutions for our customers—including potentially life-saving drugs—that to date could not be formulated.”
Acting Chairman James Little provided Dr. Panagiotou with the keys to the Center and presented founder and former CEO and Chairman, Irwin J. Gruverman, with a plaque commemorating his 25 years of service with the company.
About Microfluidics
Microfluidics, a wholly owned subsidiary of MFIC Corporation, is a supplier of advanced fluid processing equipment and reaction technology for laboratory, pilot scale and manufacturing applications. The equipment enables the manufacture and formulation of numerous nanomaterials and nanoscale products and produces the most uniform and smallest liquid and suspended solid particles available.
Microfluidics has been a worldwide supplier of Microfluidizer® high shear fluid processing systems to the Biotechnology and Pharmaceutical industries since 1984. As leader in the field, Microfluidics has enabled numerous companies and institutions to formulate, validate and produce licensed drugs for the worldwide healthcare market.
Companies seeking to produce difficult-to-formulate products or to find better methods of bio-processing can take advantage of complimentary sample testing at one of three Microfluidics facilities. Visit www.microfluidicscorp.com, e-mail <"mailto: mixinginfo@mfics.com">mixinginfo@mfics.com or contact Microfluidics at (800) 370-5452 for application information.
Industry news in brief
News Archives
All news for June 2007
All news for May 2007
26/06/2007 - LabTechnologist.com brings you its periodic round up of industry news with developments at Applied Biosystems, MFIC, Oxford Gene Technology, PerkinElmer and Syagen.
Applied Biosystems has opened a new application support centre at its R&D headquarters in foster City, California, US. The 10,000 sq.ft. facility will house a wide selection of the company's instrumentation and software offerings to allow customers to identify workflow improvements and develop new applications with the help of Applied Biosystems staff.
IntegraGen has become the first certified service provider for Illumina's GoldenGate and Infinium genotyping technologies in France.
"IntegraGen is a company dedicated to offering high-quality services to other research institutes, either private or academic, and is the first laboratory in France to achieve CSPro certification for GoldenGate and Infinium Genotyping," said Karen Possemato, director of corporate marketing at Illumina.
MFIC Corporation has opened a new R&D facility, dubbed the Microfluidics Technology Center, designed to assist in the company's quest to develop microfluidic technology for use in pharmaceutical formulation processes.
Willy, are you sure your name isn't Willy Nilly?
Good luck selling into a break out to jump back in , sheesh!
Are you being serious, what did you make like 8.5%...
These under $2 days might not be around much longer my friend...
GL
Mike
Took advantage of the spike and pulled some off the table. Will jump back in on pullback
Wow somebody is running her...
Nice late day buying in MFIC on a very dreary market day.
Alert Triggered for MFIC Corp.
MFIC Corp. (MFIC) Price Crossed Above Its 60 Day Moving Average
MFIC crossed above its 60 day moving average of $1.71 with a trade of $1.77 at 3:07 PM EDT, up 3.5% from the moving average. It is currently trading higher on the day, up 2.3% to $1.75.
Please note you will receive only one "Price Crosses its Moving Average" alert per day per stock which means that you will not get another 60 day moving average alert for MFIC.
From someone who says they attended annual meeting (and thanks):
By: andre726
21 Jun 2007, 03:40 PM EDT
Msg. 12381 of 12381
Jump to msg. #
Annual meeting
Real quick as I've got much to do during this return trip to the Boston area:
Started out with a recitation of the vote results. Interestingly, votes withheld ranged up to 800,000 for EACH of the directors. Never happened before in my experience. Still, all votes passed with 8 million or so FOR.
Official meeting adjourned. Chairman Little went through a presentation about MFIC. Not bad....perhaps even good....which included the company's alleged objective of being listed on AMEX within twelve months.
Then, questions. I was the only one who asked. There was apparently an investor or two there aside from me...but they remained silent.
First question: operating expenses far too high, sales expense in particular too high. I compared Q1 2006's $3,050,000 and Q1 2007's $2,800,000 revenues and pointed out that Q1 2007's selling expense was $200,000 plus thousand HIGHER despite its revenues being $350,000 LOWER.
Chairman Little pointed out that operating expenses were about the same as Q4 2006 (which, in my opinion, is nothing to brag about since revenues were a whopping $2,240,000 lower) and then asked Dennis Riordan to comment. He then went into his "we already answered that during the conference call and it has to do with adding new salespeople" response.
My response: "Yes. I know that's what you said during the conference call. And as I knew that the conference call was being recorded for prosperity, I didn't pursue the matter any further than I did...."
Suffice to say they had no answer to my question as to how Q1 2007's sales expense was $100,000 higher than Q3 2006 when Q3 2006 was a $3.553 million quarter (i.e., $750,000 higher than Q1 2007), especially since the new salespeople had been hired BEFORE Q3 2006. They had no answer to my question about "are they being paid $300,000 each in base annual salary in light of four new sales resources being paid $300,000 more during a single quarter as compared to Q1 2006 (the lesser Q1 2007 revenues resulting in $97,000 less in commissions being paid out such that the increase in sales expenses was actually closer to $300,000).
Dennis Riordan tried to say something about Q1 2007 actually being a $3.5 million quarter if those $800,000 worth of equipment had been shipped out by the end of Q1 2007. I asked him if any commissions were paid on those sales in that it was my understanding that commissions are paid upon shipment. He acknowledged, "No".
He then said it was something he would look into.
Second question: Japan sales. 2004 average: $625,000 per quarter. Q4 2006: $125,000. Q1 2007: $196,000. Suffice to say that, after hearing the same BS about constant pressure reducing the need for replacement parts (20 years of lab equipment sales involved NO constant pressure and only a handful of constant pressure production machines were sold to Japan since 2005), there was general recognition that there was a serious problem that needed to be looked into immediately as a top priority management exercise.
Third question related to the horrendous inconsistency in the messages delivered on March 29 and April 2.
Chairman Little said that was the last question (I actually had several more) and asked everyone to make their way to the new lab.
I figured that the lab would look very much like a lab....and left to proceed with my day.
So...the Board of Directors have been made aware of some things to be looked into. We'll see if any positive changes occur as a result.
IG was there sitting apart from other Directors. I was not made aware of any new hiring of a new IR person.
(Voluntary Disclosure: Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy)
MFIC Announces Opening of Microfluidics Technology Center
Innovation Hub Dedicated to Advancing the Micro- and Nano-Formulation Fields
Jun 21, 2007 7:00:00 AM
Copyright Business Wire 2007
NEWTON, Mass.--(BUSINESS WIRE)--
MFIC Corporation (MFIC or the Company)(OTCBB: MFIC) today announced the opening of the Microfluidics Technology Center, a state-of-the-art research and discovery facility located at the MFIC company headquarters in Newton, MA. MFIC is an industry-leader in fluid formulation processing equipment to produce the most uniform and smallest liquid and solid particles available for the biotech, pharmaceutical, chemical, personal care and food industries.
"The Microfluidics Technology Center will house our highly-specialized research team, dedicated to advancing the formulation field by developing new applications for Microfluidics' technology and pursuing groundbreaking work in the field of nanotechnology," said Dr. Thomai Panagiotou, Vice President of Research and Development. "We are very excited about the Center and believe it will serve as an innovation hub, playing a critical role in unlocking countless formulation solutions for our customers--including potentially life-saving drugs--that to date could not be formulated."
The Microfluidics Technology Center will provide customers full access to the Company's R&D engineers and complete product suite to prepare, characterize and optimize formulation samples. Engineers will also assist customers in improving their existing products through reformulation using proprietary, leading-edge, high-shear Microfluidizer(R) materials processors.
"The opening of the Center demonstrates our ongoing commitment to advancing the industry and to providing the highest quality of service to our customers," said Bob Bruno, President and Chief Operating Officer. "While we have always worked closely with customers to solve their most challenging formulation problems, the Microfluidics Technology Center will maximize this experience by providing access to the best engineers and the most advanced equipment in a single-laboratory setting designed specifically with our customers' unique needs in mind."
About MFIC Corporation:
MFIC Corporation, through its Microfluidics Division, designs, manufactures and distributes patented and proprietary high performance Microfluidizer(R) materials processing and formulation equipment to the biotechnology, pharmaceutical, chemical, cosmetics/personal care, and food industries. MFIC applies its 20 years of high pressure processing experience to produce the most uniform and smallest liquid and suspended solid particles available, and has provided manufacturing systems for nanoparticle products for more than 15 years.
The Company is a leader in advanced materials processing equipment for laboratory, pilot scale and manufacturing applications, offering innovative technology and comprehensive solutions for nanoparticles and other materials processing and production. More than 3,000 systems are in use and afford significant competitive and economic advantages to MFIC equipment customers.
Nano Nano!
BEFORE THE BELL: -2-
9:03 AM EDT June 20, 2007
Luna Innovation Up After Reporting Nano Study
Shares of Luna Innovation Inc. (LUNA) rose 12% to $5.30 after the company reported its researchers showed in a study that nanospheres were able to block an allergic response to human cell cultures experiments and mice.
The company said it was seeking pharmaceutical partnerships to develop and validate the nano-sized compounds.
Luna collaborated with Virginia Commonwealth University in the study.
Nanoparticle Offers Promise For Treating Glaucoma
Science Daily
Source: University of Central Florida
Date: June 19, 2007
A unique nanoparticle made in a laboratory at the University of Central Florida is proving promising as a drug delivery device for treating glaucoma, an eye disease that can cause blindness and affects millions of people worldwide.
“The nanoparticle can safely get past the blood-brain barrier making it an effective non-toxic tool for drug delivery,” said Sudipta Seal, an engineering professor with appointments in UCF’s Advanced Materials Processing and Analysis Center and the Nanoscience Technology Center.
Seal and his colleagues from North Dakota State University note in the article that while barely 1-3 percent of existing glaucoma medicines penetrate into the eye, earlier experiments with nanoparticles have shown not only high penetration rates but also little patient discomfort. The miniscule size of the nanoparticles makes them less abrasive than some of the complex polymers now used in most eye drops.
Seal and his team created a specialized cerium oxide nanoparticle and bound it with a compound that has been shown to block the activity of an enzyme (hCAII) believed to play a central role in causing glaucoma.
The disease involves abnormally high pressure of the fluid inside the eye, which, if left untreated, can result in damage to the optic nerve and vision loss. High pressure occurs, in part, because of a buildup of carbon dioxide inside the eye, and the compound blocks the enzyme that produces carbon dioxide.
Seal and a team of collaborators including Sanku Mallik, of North Dakota State University, developed the research on using nanoparticles as a delivery mechanism for the compound after supervising a student summer project at UCF. Duke University undergraduate Serge Reshetnikov spent a summer studying nanoscience on UCF’s Orlando campus as part of a Research Experience for Undergraduates (REU) project funded by the National Science Foundation. Reshetnikov started looking into the possibilities of using nanoparticles as drug delivery tools. Subsequent research with his advisors led to the specific application for glaucoma.
In their paper on the research, which was also supported by the National Science Foundation, Seal and Mallik note the results are “very promising” and that their nanoparticle configuration offers seemingly limitless possibilities as a non-toxic drug delivery tool.
The findings will be published in an article appearing in the June 28 issue of the Journal of Physical Chemistry C.
Note: This story has been adapted from a news release issued by University of Central Florida.
that was from their website I was just doing a little DD...
Thank you very much for that detailed explanation of what lawyers do! Now how does that affect MFIC?
McCarter and English Client Highlights
Hayward Industries, Inc.
Hayward Industries, Inc. completed the restructuring and expansion of its debt facilities with a syndicate led by Bank of America, N.A. and including JP Morgan Chase, Bank of New York, Wachovia, PNC and Sovereign. Proceeds were used to refinance Hayward's acquisition on August 25 of Goldline Controls, Inc., of Providence, a major new product line. Howard Kailes, Alan H. Fox, and Steven Bechtler represented Hayward in the debt transaction with Freshfields Bruckhaus Deringer assisting in perfecting the German and Belgian collateral and Ogilvy Renault in perfecting the Canadian collateral; Reed Smith LLP represented the bank consortiun and Bingham McCutchen LLP represented Hayward' s noteholders. Howard Kailes, Ward Laracy, Lisa Heeb and Steven Bechtler represented Hayward in the acquisition, where Hinckley, Allen & Snyder LLP represented Goldline.
--------------------------------------------------------------------------------
Lucent Technologies
McCarter & English successfully defended Lucent Technologies in a Texas federal court against a motion to certify a class action by plaintiffs alleging Cold War era injury from radar equipment. The proposed class included U.S. and NATO military personnel who claimed they were injured by ionizing radiation from radar equipment from 1958 to 1994.
Besides Lucent, the defendants were Raytheon Co., General Electric Company, ITT Industries, Inc. and Honeywell International, Inc. Plaintiffs originally filed actions in Massachusetts, New Jersey and Texas state courts. These were each removed to federal court and then transferred and consolidated before Judge Phillip R. Martinez of the Western District of Texas.
Through the long-running litigation, the McCarter & English defense team has been instrumental in securing expert reports, critical documents, generating 50 state surveys on the differences in the law on the primary legal issues, and securing expert opinions on foreign law in several European countries, nearly all of which was cited by the court in denying class certification. The team also had primary responsibility for writing the brief for the defense group.
The court decision denying class status found that common issues do not predominate because of the numerous individual factual and legal issues that had to be resolved, the laws of multiple jurisdictions that had to be applied, and the failure of the plaintiffs to demonstrate that the plaintiffs' "proffered issues [would] be central to the litigation." The court also found that a class action was not superior to individual lawsuits for two reasons. First, class actions are particularly appropriate in "negative value" cases (where the cost to bring the suit outweighs the recovered benefit), but that the plaintiffs' claims here are not negative value cases because the individual plaintiffs allege significant bodily injury. Second, a class action was likely to be unmanageable for many of the same reasons that common issues did not predominate over individual issues (individualized factual and legal issues, choice-of-law issues), as well the failure of the plaintiffs to offer any suggestions on how to deal with the manageability issues nor any evidence on manageability based on prior radiation injury cases.
The McCarter & English team included Charles F. Rysavy, J. Wylie Donald, David Quigg, and Carey Francis.
--------------------------------------------------------------------------------
McDonald's Corp., and McDonald's Restaurant of Delaware, Inc.
March 2005 - The firm received a big win in the Supreme Court of the State of Delaware in the case of Susan Rizzitiello v. McDonald's Corp., and McDonald's Restaurant of Delaware, Inc. The plaintiff was an employee of McDonald's but resigned when she was told that she was being suspended pending an investigation of inventory issues. Her appeal centers on the claim that McDonald's breached the implied covenant of good faith and fair dealing by treating her in a racially disparate manner and falsifying records in order to create a fictitious ground for terminating her employment. The Supreme Court affirmed the decision of the Superior Court, granting Summary Judgment in favor of our clients, McDonald's Corp., and McDonald's Restaurant of Delaware, Inc. Michael P. Kelly lead the defense team.
--------------------------------------------------------------------------------
Novartis Wins Key PPA Case In NJ
January 16, 2004 - With thousands of cases pending against pharmaceutical manufacturers of cold/cough medicines containing PPA (phenylpropanolamine), McCarter & English, LLP and Kaye Scholer LLP today succeeded in refuting a plaintiff’s claim that the PPA contained in Switzerland-based Novartis Consumer Health, Inc.’s Tavist-D caused her hemorrhagic stroke. This was the first jury verdict in the nation among the thousands of pending PPA cases.
The jury unanimously rejected the plaintiff’s claim that Tavist-D was defectively designed because it included PPA and that Tavist-D contained an inadequate warning. Judge Bryan Garruto, Superior Court, Middlesex County, NJ presided over the case. All cold/cough products containing PPA manufactured by Novartis and other pharmaceutical companies were voluntarily taken off the market by the manufacturers in November 2000 at the request of the FDA.
"We’re very pleased with the result and particularly happy that the jury could appreciate the scientific evidence that demonstrated that the product is not defective," said Gita Rothschild of McCarter & English, lead trial counsel in the case. "Our client, Novartis, is gratified that the jury has confirmed its consistent view that PPA was a safe and effective product when used as directed," said Randy Sherman of Kaye Scholer, national coordinating counsel for Novartis.
In addition to Ms. Rothschild, the trial team included James Herschlein of Kaye Scholer and John Brenner and Nathan Schachtman of McCarter & English. The plaintiff was represented by the law firm of Weitz & Luxenberg.
somehow I fail to see the connection! What am i missing?
Interesting!
McCarter & English, LLP
265 Franklin Street
Boston, MA 02110
T. 617-449-6500
F. 617-607-9200
www.mccarter.com
June 6, 2007
MFIC Corporation
30 Ossipee Road
P.O. Box 9101
Newton, MA 02464
Dear Sirs:
We have acted as counsel for MFIC Corporation, a Delaware corporation (the “Company”), in connection with the Registration Statement on Form S-8 (the “Registration Statement”) being filed by the Company with the Securities and Exchange Commission pursuant to the Securities Act of 1933, as amended (the “Securities Act”), relating to the offer of an aggregate of 2,236,145 shares (the “Shares”) of common stock, par value $0.01 per share, of the Company, issuable under the MFIC Corporation 2006 Stock Plan (the “Plan”).
In so acting, we have examined, and relied as to matters of fact upon, the originals, or copies certified or otherwise identified to our satisfaction, of the Restated Certificate of Incorporation, as amended, and the Amended and Restated Bylaws of the Company, the Plan, and such other certificates, records, instruments and documents, and have made such other and further investigations, as we have deemed necessary or appropriate to enable us to express the opinion set forth below. In such examination, we have assumed the genuineness of all signatures, the legal capacity of natural persons, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as certified or photostatic copies, and the authenticity of the originals of such latter documents.
Based upon the foregoing, we are of the opinion that upon issuance and delivery by the Company of the Shares pursuant to the provisions of the Plan, and payment of the purchase price therefor in accordance with the terms set forth in the Plan in cash or other consideration permitted under the Delaware General Corporation Law, the Shares issued thereunder will be legally issued, fully paid and non-assessable.
The issuance of the Shares is subject to the continuing effectiveness of the Registration Statement and the qualification, or exemption from registration, of such Shares under certain state securities laws.
--------------------------------------------------------------------------------
We hereby consent to the filing of this opinion as an exhibit to the Registration Statement. In giving the foregoing consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act, or the rules and regulations of the Securities and Exchange Commission promulgated thereunder.
Very truly yours,
/s/ McCarter & English, LLP
--------------------------------------------------------------------------------
Exhibit 23.2(a)
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statement of MFIC Corporation on Form S-8 of our report dated March 12, 2007, pertaining to the consolidated financial statements and schedules of MFIC Corporation which appears in the Annual Report on Form 10-K of MFIC Corporation for the year end December 31, 2006.
/s/ UHY LLP
Boston, Massachusetts
June 6, 2007
odd... 2 of them...
I have seen what you have seen but do not know why the two are linked.
Good sir, do you know why this keeps popping up under my MFIC news on Alphatrade?
Munder Large-Cap Growth Fund
Is MFIC a part of this growth fund?
U.S. demand for nanotechnology medical products to approach $53 billion in 2011
Demand for nanotechnology medical products will increase over 17 percent per year to $53 billion in 2011. Afterwards, the increasing flow of new nanomedicines, nanodiagnostics, and nanotech-based medical supplies and devices into the U.S. marketplace will boost demand to more than $110 billion in 2016. These and other trends are presented in "Nanotechnology in Healthcare," a new study from The Freedonia Group, Inc., a Cleveland-based industry research firm.
The critical need for new or improved therapies for many medical conditions will promote the adaptation of nanotechnology to an expanding number of pharmaceuticals. The total market for nanomedicines will command strong growth over the long term. Treatments based on humanized monoclonal antibodies, nanopolymers and nanoproteins will drive gains, with compounds for cancer, heart diseases, neurological disorders and viral infections leading new product introductions and growth opportunities.
Advances in nanotechnology will also contribute significant improvements to the quality and performance of medical diagnostic products. Nanosized monoclonal antibody labels and DNA probes will greatly enhance the speed, accuracy, capabilities and cost-effectiveness of in vitro diagnostic testing, drug discovery and medical research procedures. Nanoparticle formulations of superparamagnetic iron oxide, gadolinium, perfluorocarbon and specialty polymers will broaden in vivo imaging capabilities. Several medical supplies and devices will emerge as key applications for nanotechnology. Nanomaterials are already gaining significant demand as active ingredients of burn dressings, bone cement, bone substitutes, and dental repair and restoration products.
The greatest short-term impact of nanotechnology in health care will be in therapies and diagnostics for cancer and central nervous system disorders. Gradually, many other major diseases, as well as injuries, will be treated and detected routinely by nanotechnology products. By 2016, nanoimplants will be widely employed in orthopedic procedures and begin to gain experimental uses in tissue and neuron regeneration. By 2021, nanotechnology will serve applications that extend into most areas of critical and chronic care. Additionally, the development of monoclonal antibody and nanomaterial vaccines and, to a lesser extent, controlled-release nutritional preparations will create a large preventive medicine market.
Source: Marketwire
I'm going to try to grab some more under $2 as soon as we see any break upward... I just hope I have the free cash when the time comes...
I'm IN !!!!
High 1.70 Low 1.70
Vol 3,600 Time
10:14:10
I may take a small position here, sounds like a good promising company
Microfluidics expands in Newton
BostonGlobe.com
By Chris Reidy, Globe staff
Thursday, June 14, 2007
Microfluidics Corp. will unveil a new technology center in its home town of Newton next week.
The company specializes in Microfluidizer processors that are used in reseach-and-development laboratories as well as in pilot and production manufacturing operations; the company said its equipment enables the manufacture and formulation of numerous nano-materials and nano-scale products in the pharmaceutical, biotechnology, chemical, cosmetic, and food industries.
The center will house state-of-the-art technology and enable Microfluidics application specialists to enhance their work with potential customers to prepare physical samples, documentation, microscopic digital images, and particle-sized analysis of improved processes, the company said.
Posted by Boston Globe Business Team at 08:00 AM
Researchers Develop New Nanomaterials to Deliver Anticancer Drugs to Cells
Researchers at UCLA have successfully manipulated nanomaterials to create a new drug-delivery system that promises to solve the challenge of the poor water solubility of today's most promising anticancer drugs and thereby increase their effectiveness.
The poor solubility of anticancer drugs is one of the major problems in cancer therapy because the drugs require the addition of solvents in order to be easily absorbed into cancer cells. Unfortunately, these solvents not only dilute the potency of the drugs but create toxicity as well.
In a paper scheduled to be published in the nanoscience journal Small in June, researchers from UCLA's California NanoSystems Institute and Jonsson Cancer Center report a novel approach using silica-based nanoparticles to deliver the anticancer drug camptothecin and other water-insoluble drugs into human cancer cells.
The study is led by Fuyu Tamanoi, UCLA professor of microbiology, immunology and molecular genetics and director of the Jonsson Cancer Center's Signal Transduction and Therapeutics Program Area, and Jeffrey Zink, UCLA professor of chemistry and biochemistry.
Tamanoi and Zink devised a method for incorporating the representative hydrophobic anticancer drug camptothecin into the pores of fluorescent mesoporous silica nanoparticles and delivering the particles into a variety of human cancer cells to induce cell death. The results suggest that the mesoporous silica nanoparticles might be used as a vehicle to overcome the insolubility problem of many anticancer drugs.
"Silica nanomaterials show promise for delivering camptothecin and other water-insoluble drugs," Tamanoi said. "We have successfully loaded hydrophobic anticancer drugs into mesoporous nanoparticles and delivered them into human cancer cells to induce cell death."
"The beauty of our findings is that these nanoparticles are biocompatible, contain tubular pores and are relatively easy to modify," Zink said. "Additional modification by attaching a
ligand against a cancer-cell-specific receptor can make the nanoparticles recognizable by cancer cells."
A critical obstacle and challenge for cancer therapy is the limited availability of effective biocompatible delivery systems. Since many effective anticancer agents have poor water solubility, the development of novel delivery systems for these molecules without the use of organic solvents has received significant attention.
Camptothecin (CPT) and its derivatives are considered to be among the most effective anticancer drugs of the 21st century. Although studies have demonstrated their effectiveness against carcinomas of the stomach, colon, neck and bladder, as well as against breast cancer, small-cell lung cancer and leukemia in vitro, clinical application of CPT in humans has only been carried out with CPT derivatives that have improved water solubility.
"In order to be used on humans, current cancer therapies such as CPT or Taxol, which are poorly water soluble, must be mixed with organic solvents in order to be delivered into the body," Tamanoi said. "These elements produce toxic side effects and in fact decrease the potency of the cancer therapy."
To overcome these problems, drug delivery systems using pegylated polymers, liposomal particles or albumin-based nanoparticles have been developed.
The new research findings show that mesoporous silica nanoparticles offer great potential and a promising approach to the delivery of therapeutic agents into targeted organs or cells. The pores in the nanoparticles could be closed by constructing an appropriate cap structure. This provides the ability to control the release of anticancer drugs by external stimuli.
The research was supported by grants from the National Institutes of Health and the National Science Foundation and represents a collaboration between two totally different fields: bioscience and chemistry. The researchers came together because of their common interests in the identification of novel anticancer drugs and the potential for nano-delivery. Both Tamanoi and Zink are members of the California NanoSystems Institute at UCLA, which encourages cross-disciplinary collaboration to solve problems in nanoscience and nanotechnology.
For information about Fuyu Tamanoi's research, visit the Tamanoi Research Lab's Web site at www.mimg.ucla.edu/faculty/tamanoi.
For more information about Jeffrey Zink, visit the Zink Group Web site at www.chem.ucla.edu/dept/Faculty/zink/index.php.
About the California NanoSystems Institute
The California NanoSystems Institute (CNSI) is a multidisciplinary research center at UCLA whose mission is to encourage university-industry collaboration and to enable the rapid commercialization of discoveries in nanosystems. CNSI members include some of the world's preeminent scientists, and the work conducted at the institute represents world-class expertise in five targeted areas of nanosystems-related research: renewable energy; environmental
nanotechnology and nanotoxicology; nanobiotechnology and biomaterials; nanomechanical and nanofluidic systems; and nanoelectronics, photonics and architectonics. For additional information, visit the CNSI Web site at www.cnsi.ucla.edu.
About UCLA
UCLA is California's largest university, with an enrollment of nearly 37,000 undergraduate and graduate students. The UCLA College of Letters and Science and the university's 11 professional schools feature renowned faculty and offer more than 300 degree programs and majors. UCLA is a national and international leader in the breadth and quality of its academic, research, health care, cultural, continuing education and athletic programs. Four alumni and five faculty have been awarded the Nobel Prize.
Wednesday, June 06, 2007
University of California Los Angeles
Media Contacts:
Kim Irwin
(310) 206-2805
(310) 794-0777
kirwin@support.ucla.edu
Additional Resources:
Jennifer Marcus
UCLA
(310) 267-4839
jmarcus@cnsi.ucla.edu
Yep, I'm going to have to grab a few more under $2 here when I get some loose change...
What I liked best in the Taglich report about MFIC were the comments that "the advent of MRT could potentilly unlock uncounted drugs, vaccines and drug delivery systems that to date could not be formulated. Bruno (MFIC's President) further stated that MRT provides a critical advancement in the field of drug formulation and positions MFIC as a clear technology leader. The Company anticipateds introducing a line of equipment to facilitate the MRT process in the fourth quarter of fiscal 2007."
New Taglich Bros. Research Report maintaining MFIC at Speculative Buy:
http://www.taglichbrothers.com/equityuniverse/companies/mficcorp/mficcorp-06042007.pdf
:- )
I'm sure any # of my current "longs" are going to provide that cash any minute now. <g>
forget about it....
If I had some "forget about it cash" right now I would :- )
Yep, this is a good one to buy it and forget about it....
Followers
|
5
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
675
|
Created
|
12/30/04
|
Type
|
Free
|
Moderators |
Featured Event
Microfluidizer® High Shear ProcessorsMicrofluidics, a division of Microfluidics International Corporation, pioneered the Microfluidizer® high pressure fluids processor which delivers unique product capabilities, including unparalleled cell disruption rates, particle size reduction to nano-sized particles for dispersions, emulsions, liposomes, and deagglomerations. Microfluidizer processors are used in research and development laboratories, as well as pilot and production manufacturing operations, where scaleup on your product is guaranteed. The Microfluidizer high shear processor technology is widely used to formulate innovative new products in the pharmaceutical, biotechnology, food, chemical and personal care industries. Download a pdf of our General Brochure.
Learn more about Microfluidizer processors and how they compare to traditional homogenizers and mills. Microfluidics offers a complete line of Microfluidizer® fluid processors for deagglomeration and dispersion of uniform submicron particles and creation of stable emulsions and dispersions. Microfluidizer processors overcome limitations of conventional processing technologies by utilizing high-pressure streams that collide at ultra-high velocities in precisely defined microchannels. Combined forces of shear and impact act upon products to create finer, more uniform dispersions and emulsions than can be produced by any other means. To see how a Microfluidizer processor works watch our flash demo now. Our applications laboratory can help you develop innovative products or investigate reformulation of existing products to new levels of quality. And, with all Microfluidizer fluids processors, Microfluidics guarantees scaleup. Follow the links to see some of our specific high shear processors, which we manufacture in several sizes for a variety of uses. Or schedule a Free On-Site Demonstration or a Free Sample Test in our Laboratory. As part of its global distribution expansion plans, Microfluidics has increased its presence with new sales representatives and partnerships in
More details one each partner can be found on the 'rep section ' of the web site.
|
http://www.microfluidicscorp.com/
Microfluidics, a division of MFIC Corporation, pioneered the Microfluidizer® high pressure fluids processor which delivers unique product capabilities, including unparalleled cell disruption rates, particle size reduction to nano-sized particles for dispersions, emulsions, liposomes, and deagglomerations. Microfluidizer processors are used in research and development laboratories, as well as pilot and production manufacturing operations, where scaleup on your product is guaranteed. The Microfluidizer high shear processor technology is widely used in the pharmaceutical, biotechnology, digital ink, microelectronics, food, chemical and personal care industries.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |